# INBRX-106

Source: https://onco.cc/drugs/inbrx-106/  
OnCo record `inbrx-106` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.

## Summary

INBRX-106 is a monoclonal antibody developed by Inhibrx Biosciences. The sponsor describes its target as OX40, which OnCo does not yet have a target page for. The sponsor states: A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies. ClinicalTrials.gov describes the intervention as: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06295731 (INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC), in head and neck squamous cell carcinoma. The largest, NCT06295731, plans to enrol 410 participants with primary completion expected 2029-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Hexavalent OX40 agonist antibody
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: A hexavalent OX40 agonist antibody designed to promote hyperclustering of OX40, giving more potent activation of the OX40 costimulatory pathway than traditional Fc-crosslinking-dependent bivalent OX40 antibodies.

## Sources

- ClinicalTrials.gov: trials of INBRX-106: https://clinicaltrials.gov/search?intr=INBRX-106
- Sponsor pipeline page: https://inhibrx.com/pipeline/

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Inhibrx Biosciences](https://onco.cc/companies/inhibrx/)
- trials: [INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC](https://onco.cc/trials/nct06295731/), [Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients](https://onco.cc/trials/nct06353997/)
- targets: [OX40 (TNFRSF4)](https://onco.cc/targets/tnfrsf4/)

---
JSON: https://onco.cc/api/v1/entities/inbrx-106.json